Polyethylene glycol-modified interleukin-2 and thymosin α1 in human immunodeficiency virus type 1 infection

Journal of Infectious Diseases

Volumn 173, Issue 4, 1996, Pages 1005-1008

  Ramachandran, R ^a   Katzenstein, D A ^a   Winters, M A ^a   Kundu, S K ^a   Merigan Jr , Thomas C ^a,b  

^a STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 2; MACROGOL; ZIDOVUDINE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG DESIGN; DRUG EFFECT; DRUG TOLERABILITY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAVENOUS DRUG ADMINISTRATION; LYMPHOCYTE COUNT; MALE; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; T LYMPHOCYTE; VIRUS ACTIVATION;

EID: 0029973267     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/173.4.1005     Document Type: Article

References (14)

1. Masur H, Ognibene FP, Yarchoan R, et al. CD4 counts as predictors of opportunistic pneumonias in HIV infection. Ann Intern Med 1989;111:223-31.
2. Taniguchi T, Matsui H, Fujita T, et al. Structure and expression of a cloned cDNA for human interleukin-2. Nature 1983;302:305-10.
3. Schwartz DH, Skowron G, Merigan TC. Safety and effects of interleukin-2 plus zidovudine in asymptomatic individuals infected with human immunodeficiency virus. J Acquir Immune Defic Syndr 1992;4:11-23.
4. Clark AGB, Holodniy M, Schwartz DH, Katzenstein DA, Merigan TC. Decrease in HIV provirus in peripheral blood mononuclear cells during zidòvudine and rIL-2 administration. J Acquir Immune Defic Syndr 1992;5:52-9.
5. Wood R, Montoya JG, Kundu SK, Schwartz DH, Merigan TC. Safety and efficacy of polyethylene glycol - modified interleukin-2 and zidovudine in human immunodeficiency virus type 1 infection, a phase I/II study. J Infect Dis 1993;167:519-25.
6. Goldstein AL, Low TL, Adoo M, et al. Thymosin alpha 1 isolation and sequence analysis of an immunologically active thymic peptide. Proc Natl Acad Sci USA 1977;74:725.
7. Schulof RS. Phase I/II trial of thymosin fraction 5 and thymosin alpha 1 in HTLV-III seropositive subjects. J Biol Response Modif 1986;3:429-43.
8. Garaci E, Rocchi G, Perroni L, et al. Combination treatment with zidovudine, thymosin α, and interferon-α in human immunodeficiency virus infection. Int J Clin Lab Res 1994;24:23-8.
9. Wood R, Dong H, Katzenstein DA, Merigan TC. Quantification and comparison of HIV-1 proviral load in peripheral blood mononuclear cells and isolated CD4 T cells. J Acquir Immune Defic Syndr 1993;6:237-40.
10. Winters MA, Tan L, Katzenstein D, Merigan TC. Biological variation and quality control of plasma HIV RNA quantification by RT-PCR. J Clin Microbiol 1993;11:2960-6.
11. Kovacs JA, Baesler B, Dewar R, et al. Increase in CD4 lymphocytes with intermittent courses of interleukin-2 in patients with human immunodeficiency virus infection - α preliminary study. N Engl J Med 1995;332:567-75.
12. Schnittman SM, Vogel S, Baseler M, Lane HC, Davey RT Jr. A phase I study of interferon-α2b in combination with interleukin-2 in patients with human immunodeficiency virus infection. J Infect Dis 1994;169:981-9.
13. Kozal MJ, Winters MA, Katzenstein DA, Merigan TC. A mutation in human immunodeficiency virus reverse transcriptase and decline in CD4 lymphocyte numbers in long-term zidovudine recipients. J Infect Dis 1993;167:526-32.
14. Goldstein AL, Garaci E. Combination anti-HIV therapies 2. New York: Plenum Press, 1992:275-80.